N
Neeraj Dhaun
Researcher at University of Edinburgh
Publications - 179
Citations - 4049
Neeraj Dhaun is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 29, co-authored 152 publications receiving 3048 citations. Previous affiliations of Neeraj Dhaun include British Heart Foundation & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Circulating microRNAs as potential markers of human drug‐induced liver injury
Philip J. Starkey Lewis,James W. Dear,Vivien Platt,Kenneth J. Simpson,Darren G. Craig,Daniel J. Antoine,Neil French,Neeraj Dhaun,David J. Webb,Eithne Costello,John P. Neoptolemos,Jonathan G. Moggs,Christopher E. Goldring,B. Kevin Park +13 more
TL;DR: This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug‐induced liver injury by examining these molecules, for the first time, in humans with APAP poisoning.
Journal ArticleDOI
The Endothelin System and Its Antagonism in Chronic Kidney Disease
TL;DR: Data are emerging to suggest a synergistic role for ET receptor antagonists with angiotensin-converting enzyme inhibitors in slowing CKD progression and antagonism of the ET system may be of benefit in improving renal hemodynamics and reducing proteinuria.
Journal ArticleDOI
Role of Endothelin-1 in Clinical Hypertension 20 Years On
Neeraj Dhaun,Jane Goddard,Donald E. Kohan,David M. Pollock,Ernesto L. Schiffrin,David J. Webb +5 more
TL;DR: Questions about the potential role that ET-1 may play in the development of hypertension and the lack of longer-term data on safety and tolerability for these drugs made their place in the antihypertensive armamentarium unclear are aimed at answering.
Journal ArticleDOI
Endothelins in cardiovascular biology and therapeutics.
Neeraj Dhaun,David J. Webb +1 more
TL;DR: Endothelin 1 is the most potent vasoconstrictor in the human cardiovascular system and contributes to basal vascular tone as well as a number of diseases, such as hypertension, chronic kidney disease, pulmonary arterial hypertension, PAH and pre-eclampsia.
Journal ArticleDOI
Management of Hypertension in Chronic Kidney Disease.
TL;DR: A personalised and evidence-based management plan remains key to achieving BP targets, reducing CVD risk and slowing progression of CKD.